Business Wire

MD-GET-REAL-HEALTH

Share
Get Real Health Announces Further International Expansion to Bring Patient Engagement Tools Into The Netherlands

Get Real Health, a member of the CPSI (NASDAQ: CPSI) family of companies and a provider of comprehensive patient engagement tools, has expanded its international presence through an implementation in the region of Achterhoek, Netherlands, together with local partners MIJNPGO and WeDoTrust.

This implementation is meant to support the region’s ambition to become the healthiest region in the Netherlands by 2030. To that end, the project will have timed implementations and deployments aimed at improving healthcare across all demographics.

The Achterhoek solution is based on Get Real Health’s existing platform, and is customized for the region’s needs and called “MIJNPGO.” This customization effort includes ensuring compliance with Medmij, the technology standard across the Netherlands, which requires the secure exchange of data between care providers and patients. The initial pilot served a select cohort of care organizations including Sensire, the largest elderly care organization in the region. An expanded roll-out will utilize feedback and aim at improving the user experience over time.

“We are thrilled to participate in this important initiative. Our platform perfectly aligns with the mission of Achterhoek with respect to improved healthcare delivery and patient care outcomes both today and into the future,” said Robin Wiener, president of Get Real Health.

“In the Dutch region of Achterhoek, we are constantly working on adding more professional applications of modern technology in healthcare, together with other healthcare organizations and partners,” said Maarten van Rixtel, chief executive officer of Sensire, the largest elderly care organization in the region. “With MIJNPGO, the patients gain more insight into their own health. In addition, patients can share information with healthcare workers or caregivers. MIJNPGO therefore gives patients much more control over their own care and treatment process. This creates equal discussions and certain decisions can be made jointly. For us, MIJNPGO is one of the fundamental bases of healthcare for the future. We are looking forward to the moment when MIJNPGO will be used by many patients.”

Following the initial launch of the pilot in 2020, Get Real Health expanded the release of the platform at the end of August 2021, along with a website design refresh and portal upgrade to improve patient outcomes, enhance health, and implement a more engaging platform to the overall user base.

Through similar deployments in Canada, New Zealand, the Middle East and the United Kingdom, Get Real Health has established itself as an international presence in the patient engagement arena. “We see patient engagement as a global issue, and we develop applications with that philosophy in mind,” explained Wiener. “Our platform is flexible and scalable to serve individuals worldwide.”

About Get Real Health

Get Real Health, a member of the CPSI family of companies, combines a world of new information from patients, devices and apps with existing clinical data to help individuals and healthcare professionals engage and empower each other. By giving providers and patients the information and tools that they need to work together, we help our customers meet their ever-changing patient engagement needs. Our suite of products helps deliver value-based care, improve outcomes, activate patients, and increase patient loyalty and satisfaction, all while meeting regulatory requirements. For more information, visit www.getrealhealth.com .

About WeDoTrust

WeDoTrust is a consultancy and audit company. They assist healthcare institutions, among other things, in drawing up a realistic digital change agenda based on their strategy and financial possibilities. In doing so, they take into account the strength of the organization, market demand and the (im)possibilities of technology.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “projects,” “targets,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the success of Get Real Health’s solutions in the region of Achterhoek, Netherlands, are forward-looking statements. We caution investors that any such forward-looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward-looking statements. Such factors may include: the ability of Get Real Health’s technology and tools to successfully provide patients with more control over their healthcare information and allow greater accessibility to clinical teams and health records; the ability of Get Real Health’s platform to comply with the Medmij technology standard; the impact of the ongoing COVID-19 pandemic and related economic disruptions which have materially affected CPSI’s revenue and could materially affect CPSI’s gross margin and income, as well as CPSI’s financial position and/or liquidity; actions to be taken by CPSI in response to the pandemic; the legal, regulatory and administrative developments that occur at the federal, state and local levels; changes in revenues due to declining hospital demand and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); CPSI’s potential inability to attract and retain qualified client service and support personnel, as well as the disruptive effect of sales force restructurings; exposure to numerous laws, regulations and other requirements through CPSI’s international business activities; potential failure to develop or enhance products in response to market demands, as well as undetected errors or problems in new products or enhancements; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of CPSI’s or its partners’ information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; dependence on licenses of rights, products and services from third parties; service interruptions resulting from loss of power and/or telecommunications capabilities; potential increased expenses related to labor or other expenditures; the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms or at all, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financial perspective; and other risk factors described from time to time in CPSI’s public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, CPSI’s most recent Annual Report on Form 10-K. We also caution investors that the forward-looking information described herein represents CPSI’s outlook only as of this date, and CPSI undertakes no obligation to update or revise any forward-looking statements to reflect events or development after the date of this press release.

Link:

ClickThru

Social Media:

https://www.facebook.com/GetRealHealth/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye